APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome
|
By LabMedica International staff writers Posted on 22 Jul 2021 |

Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)
Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.
The apolipoprotein E (APOE) ε4 allele is the most established genetic risk factor for sporadic AD and has been consistently associated with earlier AD symptoms and pathology in the general population. A similar disease-accelerating feature might exist in DS given that studies in this population have reported that ɛ4 allele carriers show an earlier onset of clinical symptoms and greater amyloid burden than non-carriers.
An international team of Neurologists and their colleagues led by those at the Hospital of the Holy Cross and Saint Paul (Barcelona, Spain) recruited adults with DS. In Barcelona, Spain, adults with DS were recruited from a population-based health plan that was developed for the screening of AD from which the Down Alzheimer Barcelona Neuroimaging Initiative cohort. In the UK, participants were selected from a convenience sample that was recruited from services for people with intellectual disabilities in England and Scotland. Of 464 participants, 97 were APOE ε4 carriers and 367 were non-carriers.
DNA was extracted from peripheral blood by technicians who were blinded to clinical and biomarker data, and APOE genotyping was determined by polymerase chain reaction amplification. Participants were dichotomized according to the presence of at least one ɛ4 allele. Plasma levels of phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) were measured using single molecule array technology (Simoa; Quanterix, Billerica, MA, USA). The CSF levels of amyloid-β peptide 1-40 (Aβ1-40), Aβ1-42, pTau181, and total tau were quantified using a fully automated platform (Lumipulse; Fujirebio, Malvern, PA, USA). The CSF NfL levels were measured with enzyme-linked immunosorbent assay (NF-Light Assay; UmanDiagnostics, Umeå, Sweden).
The investigators reported that no differences between the two groups were found by age or sex (51 male carriers [52.6%] versus 199 male non-carriers [54.2%]). APOE ɛ4 allele carriers compared with non-carriers presented with AD symptoms at a younger age and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by non-overlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ɛ4 allele carriers.
The authors concluded that APOE ɛ4 allele carriers (compared with non-carriers) showed an earlier decline in episodic memory, earlier clinical diagnosis of symptomatic AD, earlier changes in AD biomarkers, and differences in the pattern of neurodegeneration. These findings demonstrated that the APOE ɛ4 allele can modulate both the clinical expression and biomarkers of AD in a genetic form of the disease, such as in DS, and emphasize the importance of the APOE genotype for future clinical trials in DS. The study was published on July 6, 2021 in the journal JAMA Neurology.
Related Links:
Hospital of the Holy Cross and Saint Paul
Quanterix
Fujirebio
UmanDiagnostics
The apolipoprotein E (APOE) ε4 allele is the most established genetic risk factor for sporadic AD and has been consistently associated with earlier AD symptoms and pathology in the general population. A similar disease-accelerating feature might exist in DS given that studies in this population have reported that ɛ4 allele carriers show an earlier onset of clinical symptoms and greater amyloid burden than non-carriers.
An international team of Neurologists and their colleagues led by those at the Hospital of the Holy Cross and Saint Paul (Barcelona, Spain) recruited adults with DS. In Barcelona, Spain, adults with DS were recruited from a population-based health plan that was developed for the screening of AD from which the Down Alzheimer Barcelona Neuroimaging Initiative cohort. In the UK, participants were selected from a convenience sample that was recruited from services for people with intellectual disabilities in England and Scotland. Of 464 participants, 97 were APOE ε4 carriers and 367 were non-carriers.
DNA was extracted from peripheral blood by technicians who were blinded to clinical and biomarker data, and APOE genotyping was determined by polymerase chain reaction amplification. Participants were dichotomized according to the presence of at least one ɛ4 allele. Plasma levels of phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) were measured using single molecule array technology (Simoa; Quanterix, Billerica, MA, USA). The CSF levels of amyloid-β peptide 1-40 (Aβ1-40), Aβ1-42, pTau181, and total tau were quantified using a fully automated platform (Lumipulse; Fujirebio, Malvern, PA, USA). The CSF NfL levels were measured with enzyme-linked immunosorbent assay (NF-Light Assay; UmanDiagnostics, Umeå, Sweden).
The investigators reported that no differences between the two groups were found by age or sex (51 male carriers [52.6%] versus 199 male non-carriers [54.2%]). APOE ɛ4 allele carriers compared with non-carriers presented with AD symptoms at a younger age and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by non-overlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ɛ4 allele carriers.
The authors concluded that APOE ɛ4 allele carriers (compared with non-carriers) showed an earlier decline in episodic memory, earlier clinical diagnosis of symptomatic AD, earlier changes in AD biomarkers, and differences in the pattern of neurodegeneration. These findings demonstrated that the APOE ɛ4 allele can modulate both the clinical expression and biomarkers of AD in a genetic form of the disease, such as in DS, and emphasize the importance of the APOE genotype for future clinical trials in DS. The study was published on July 6, 2021 in the journal JAMA Neurology.
Related Links:
Hospital of the Holy Cross and Saint Paul
Quanterix
Fujirebio
UmanDiagnostics
Latest Clinical Chem. News
- Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
- FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
- Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease
- AI Predicts Kidney Stone Composition From Routine Urine Tests
- Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
- Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
- Blood and Spinal Fluid Biomarker May Help Track Early Huntington’s Disease
- New Biomarker Offers Longer Detection Window for Suspected GHB Exposure
- Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction
- Flow Cytometry Tests Receive FDA Clearance for B-Cell Lymphoma Diagnosis
- Blood Protein Signatures May Predict Brain Vessel Damage and Cognitive Decline
- Combined Blood and Imaging Data Help Identify More Lung Cancer Cases
- Blood Protein Panel Detects ALS with High Accuracy
- Single-Vesicle Analysis Reveals Tissue-Associated Inflammatory Signatures
- Plasma Proteomic Test Detects Immunotherapy Resistance Before Imaging in Lung Cancer
- Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







